Cellular and molecular biology of fibrous dysplasia;Biologie cellulaire et moléculaire de la dysplasie fibreuse

Annales de Pathologie

Volumn 21, Issue 6, 2001, Pages 489-498

  Marie, Pierre ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Bone formation; Fibrous dysplasia; Gs ; McCune Albright syndrome; Mutations; Osteoblasts

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; COLLAGEN FIBER; OSTEONECTIN; OSTEOPONTIN; SIALOPROTEIN;

ALBRIGHT SYNDROME; ALPHA CHAIN; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; FIBROUS DYSPLASIA; GENE MUTATION; MOLECULAR BIOLOGY; ONCOGENE C FOS; OSTEOBLAST; PROTEIN SYNTHESIS; PROTO ONCOGENE;

CELL DIFFERENTIATION; CELL DIVISION; COLLAGEN; FIBROUS DYSPLASIA OF BONE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; MUTATION; OSTEOBLASTS; OSTEONECTIN; OSTEOPONTIN; SIALOGLYCOPROTEINS;

EID: 18144440300     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Syndrome characterized by osteotis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females: Report of five cases
2. Osteotis fibrosa cystica; the case of a nine years old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism
3. The natural history of fibrous dysplasia
4. Fibrous dysplasia
5. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: Site-specific patterns and recurrent histological hallmarks
6. An activating Gs mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome
7. Increased proliferation of osteoblastic cells expressing the activating Gsα mutation in monostotic and polyostotic fibrous dysplasia
8. A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to expressions of c-fos and c-jun products and bone matrix proteins: A clinicopathologic review and immunohistochemical study of c-fos, c-jun, type 1 collagen, osteonectin, osteopontin, and osteocalcin
9. Expression of osteocalcin and its transcriptional regulators core-binding Factor alpha 1 and MSX2 in osteoid-forming tumours
10. Role of Cbfal in osteoblast differentiation and function
11. Stimulus-selective inhibition of rat osteocalcin promoter induction and protein-DNA interactions by the homeo-domain repressor Msx2
12. Receptor-effector coupling by G proteins: Implications for normal and abnormal signal transduction
13. s and stimulate adenylate cyclase in human pituitary tumours
14. Two G protein oncogenes in human endocrine tumors
15. s protein
16. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase
17. Further evidence for a somatic mutation theory in the pathogenesis of human pituitary tumors
18. Abnormalities in G protein-coupled signal transduction pathways in human disease
19. Genetic basis of endocrine disease. Mutations in G proteins and G protein-coupled receptors in endocrine disease
20. G protein defects in signal transduction
21. Activating mutations of the stimulator G protein in the McCune-Albright syndrome
22. McCune-Albright syndrome
23. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome
24. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein Gs
25. An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gsα-subunit from a bone lesion
26. Clinical implications of genetic defects in G proteins oncogenic mutations in G alpha s as the molecular base McCune-Albright syndrome
27. An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome
28. Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gsα gene
29. Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg201 mutations in Galpha s from patients with fibrous dysplasia of bone
30. Fibrous dysplasia of bone in the McCune-Albright syndrome: Abnormalities in bone formation
31. Growth hormone-prolactin-thyrotropin-secreting pituitary adenoma in atypical McCune-Albright syndrome with functionally normal Gs alpha protein
32. Recurrent chromosome aberrations in fibrous dysplasia of the bone: A report of the CHAMP study group. Chromosomes and morphology
33. The McCune-Albright syndrome: A lethal gene surviving by mosaicism
34. Activating mutations of Gs protein in monostotic fibrous lesions of bone
35. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy
36. Etiology os fibrous dysplasia and McCune-Albright syndrome
37. Mutations of the GNASI gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone
38. Glucocorticoids decrease interleukin-6 levels and induce mineralization of cultured osteogenic cells from children with fibrous dysplasia
39. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsα-mutated skeletal progenitor cells
40. Signal transduction and gene control: The cAMP pathway
41. Regulation of cAMP-inducible genes by CREB
42. Expression of constitutively active Gs alpha-subunits in GH3 pituitary cells stimulates prolactin promoter activity
43. sa mutants associated with human pituitary tumors: Stimulation of adenosine 3′, 5′-monophosphate response element-binding protein-mediated transcription and of prolactin and growth hormone promoter activity via protein kinase A
44. Distinct effects of calcium- and cyclic AMP-enhancing factors on cytoskeletal synthesis and assembly in mouse osteoblastic cells
45. Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone
46. Osteonectin promoter: DNA sequence analysis and S1 endonuclease site potentially associated with transcriptional control in bone cells
47. The human bone sialoprotein gene: Genomic imocalization and characterization
48. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation
49. Induction of proto-oncogene fos transcription through the adenylate cyclase pathway: Characterization of a cAMP-responsive element
50. Genomic effects of the putative oncogene Gs
51. Signaling pathways and c-fos transcriptional response - Links to inherited diseases
52. Fos and bone cell development: Lessons from a nuclear oncogene
53. Phenotype suppression: A postulated molecular mechanism for mediating the relationship of proliferation and differentiation by Fos/Jun interactions at AP-1 sites in steroid responsive promoter elements of tissue-specific genes
54. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia
55. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas
56. Malignant transformation of fibrous dysplasia. A case report and review of the literature
57. Primary response genes induced by growth factors and tumor promoters
58. Osteoblasts are target cells for transformation in c-fos transgenic mice
59. Temporal variation of c-Fos proto-oncogene expression during osteoblast differentiation and osteogenesis in developing rat bone
60. c-fos protooncogene is involved in the mitogenic effect of transforming growth factor-beta in osteoblastic cells
61. Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome
62. Increased interleukin-6 production in mouse osteoblastic MC3T3-E1 cells expressing activating mutant of the stimulatory G protein
63. The biology of interleukin-6
64. Increased osteoclast development after estrogen loss: Mediation by interleukin-6
65. Interleukin-6: An osteotropic factor?
66. New factors controlling bone remodeling
67. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
68. Estrogen receptors in bone in a patient with polyostotic fibrous dysplasia (McCune-Albright syndrome)
69. Sex steroid hormone receptors in normal and dysplastic bone disorders in children
70. Molecular and cellular mechanisms of estrogen action on the skeleton
71. Osteoblasts and bone formation
72. Parathyroid hormone-related protein in the aetiology of fibrous dysplasia of bone in the McCune-Albright syndrome
73. McCune-Albright syndrome
74. McCune-Albright syndrome and acromegaly: Clinical studies and responses to treatment in five cases
75. Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome
76. Secondary central precocious puberty in a girl with McCune-Albright syndrome responds to treatment with GnRH analogue
77. Ketoconazole treatment of gonadotropin independent precocious puberty in girls with McCune-Albright syndrome: A preliminary report
78. Fibrous dysplasia. An analysis of options for treatment
79. Polyostotic fibrous dysplasia with contrasting responses to calcitonin and mithramycin: Aetiological and therapeutic implications
80. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone
81. Long-term aminobisphosphonate treatment of fibrous dysplasia: Spectacular increase in bone density
82. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone
83. Effect of tiludronate in fibrous dysplasia of bone. A case-report
84. Bisphosphonate therapy in fibrous dysplasia
85. Pamidronate treatment of bone fibrous dysplasia in children with McCune-Albright syndrome
86. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome
87. Fibrous dysplasia of bone